Increased plasma plasminogen activator inhibitor-1 levels: A possible marker of hypertensive target organ damage

Clinical and Experimental Hypertension

Volumn 25, Issue 1, 2003, Pages 1-9

  Diamantopoulos, Emmanuel J ^a,c   Andreadis, Emmanuel A ^a   Vassilopoulos, Charalambos V ^a   Theodorides, Theodoros G ^b   Giannakopoulos, Nikolaos S ^a   Chatzis, Nikolaos A ^a   Christopoulou Kokkinou, Vana D ^b  

^a 4th Department of Internal Medicine   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Carotid intimamedia thickness; Left ventricular mass; Microalbuminuria; Plasminogen activator inhibitor 1

Indexed keywords

ANTIFIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD LEVEL; BODY SURFACE; DISEASE COURSE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORGAN INJURY; TARGET ORGAN; THROMBOSIS; TURBIDIMETRY;

ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CAROTID ARTERIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUNICA INTIMA; TUNICA MEDIA;

EID: 0037275192     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-120017736     Document Type: Article

References (16)

1. Kruithof EKO, Nicolosa G, Bachmann F et al. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observation on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70:1645-1653.
2. Margaglione M, Di Minno G, Grandone E et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14:1741-1745.
3. Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98:2241-2247.
4. Francis RB Jr, Kawanishi D, Baruch T et al. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115:776-780.
5. Meade TW, Ruddock V, Stinling W et al. Fibrinolytic activity, clotting factors, and long term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
6. Pontremoli R, Sofia A, Ravera M et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the Magic study. Hypertension 1997; 30:1135-1143.
7. Damsgaard EM, Froland A, Jorgenesen OD et al. Microalbuminuria as predictor of increased mortality in elderly people. Br Med J 1990; 300:297-300.
8. Lyungman S, Winkstrand J, Hartford M et al. Urinary albumin excretion-A predictor of risk of cardiovascular disease. Am J Hypertens 1996; 9:770-778.
9. Pontremoli R, Ravera M, Bezande GP et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17:993-1000.
10. Declerck PJ, Alessi MC, Verstreken M et al. Measurement of plasminogen activator inhibitor-1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71:220-225.
11. Sahn DJ, DeMaria A, Kisslo J et al. Recommendations regarding quantification in M-Mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
12. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55:613-618.
13. SERA-PAK immuno microalbumin. Publication No. TL9-6932K96, Bayer Corporation, 1996.
14. Juhan-Vague I, Alessi MC, Vague P et al. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothombosis. Diabetologia 1991; 34:457-462.
15. Bloor CM, Nimmo L, McKirnan MD et al. Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy. Mol Cell Biochem 1997; 176:265-271.
16. Marchesi E, Martignoni A, Tinelli C et al. Plasminogen activator inhibitor-1 and carotid intima-media thickening in patients with newly detected primary hypertension. J Cardiovasc Risk 1999; 6:363-369.